We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Read MoreHide Full Article
Terumo Corporation (TRUMY - Free Report) subsidiary MicroVention, Inc. recently announced the results of the SOFAST study in the Journal of Neurointerventional Surgery (JNIS). This prospective, multicenter study evaluated the efficacy and safety of the SOFIA Flow Plus Aspiration Catheter (SOFIA 6F) in treating acute ischemic stroke caused by large vessel occlusion.
Data from the study involving 108 patients showed that 66.7% of the patients experienced good functional outcomes at 90 days after undergoing endovascular stroke thrombectomy procedures. The company stated that the rate of “good clinical outcomes” in the study is among the very best reported with contemporary thrombectomy devices.
Significance of SOFAST
Data from the landmark SOFAST study demonstrates the robust performance of the SOFIA Flow Plus Aspiration Catheter. The catheter system achieved a 75% first-pass mTICI≥2b rate and a high overall revascularization rate of 97.2% at the procedure's end.
The SOFIA system achieved a median time of 12 minutes and 17 minutes for groin puncture to clot contact time and groin puncture to recanalization time, respectively. There was no occurrence of embolization to new territories and symptomatic intracranial hemorrhage rate within 24 hours.
These impressive metrics set a new standard for stroke thrombectomy devices, highlighting the SOFIA Aspiration System's potential to improve patient outcomes in acute ischemic stroke treatment significantly.
MicroVention now offers a fully integrated and streamlined portfolio of stroke solutions, from access to revascularization. Its product lineup includes SOFIA and SOFIA Flow Plus Aspiration Catheters, the ERIC Retrieval Device, the BOBBY Balloon Guide Catheter, the WEDGE Microcatheter, HEADWAY Microcatheters and TRAXCESS Guidewires, ensuring comprehensive care for stroke treatment.
Industry Prospects
Per a report by Verified Market Reports, the global acute ischemic stroke treatment market was worth $9.21 billion in 2023. It is anticipated to reach $19.05 billion by the end of 2030 at a CAGR of 4%
The robust growth is due to the current trends in acute ischemic stroke treatment and diagnosis, highlighting a move toward advanced imaging technologies for timely and precise diagnosis. The increasing popularity of telemedicine and remote monitoring makes timely interventions more accessible. Furthermore, state-of-the-art methods for improving patient outcomes include customized treatment plans and novel therapeutic approaches.
Recent Developments
Last month,MicroVention announced the commercial availability of the LVIS EVO Intraluminal Support Device in the United States for treating wide neck intracranial aneurysms. Available in Europe since 2019, with over 12,000 units sold, the LVIS EVO is the first fully visible coil-assist intracranial stent in the U.S. market. The device features DFT wire construction and an advanced braid design for enhanced visualization, optimized opening and precise placement, ensuring wall apposition confirmation.
Price Performance
Shares of Terumo have risen 6.7% so far this year compared with the industry's 3.7% rise. The S&P 500 has witnessed an 18.2% rise in the same time frame.
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 34.2% compared with the industry’s 4.5% rise so far this year.
Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.80%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%.
Universal Health Services has gained 20.4% compared with the industry's17.5% so far this year.
DexCom, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 22.9%. DXCM’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 34.10%.
DexCom’s shares have declined 9.4% against the industry's 3.5% increase so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Terumo Corporation (TRUMY - Free Report) subsidiary MicroVention, Inc. recently announced the results of the SOFAST study in the Journal of Neurointerventional Surgery (JNIS). This prospective, multicenter study evaluated the efficacy and safety of the SOFIA Flow Plus Aspiration Catheter (SOFIA 6F) in treating acute ischemic stroke caused by large vessel occlusion.
Data from the study involving 108 patients showed that 66.7% of the patients experienced good functional outcomes at 90 days after undergoing endovascular stroke thrombectomy procedures. The company stated that the rate of “good clinical outcomes” in the study is among the very best reported with contemporary thrombectomy devices.
Significance of SOFAST
Data from the landmark SOFAST study demonstrates the robust performance of the SOFIA Flow Plus Aspiration Catheter. The catheter system achieved a 75% first-pass mTICI≥2b rate and a high overall revascularization rate of 97.2% at the procedure's end.
The SOFIA system achieved a median time of 12 minutes and 17 minutes for groin puncture to clot contact time and groin puncture to recanalization time, respectively. There was no occurrence of embolization to new territories and symptomatic intracranial hemorrhage rate within 24 hours.
These impressive metrics set a new standard for stroke thrombectomy devices, highlighting the SOFIA Aspiration System's potential to improve patient outcomes in acute ischemic stroke treatment significantly.
MicroVention now offers a fully integrated and streamlined portfolio of stroke solutions, from access to revascularization. Its product lineup includes SOFIA and SOFIA Flow Plus Aspiration Catheters, the ERIC Retrieval Device, the BOBBY Balloon Guide Catheter, the WEDGE Microcatheter, HEADWAY Microcatheters and TRAXCESS Guidewires, ensuring comprehensive care for stroke treatment.
Industry Prospects
Per a report by Verified Market Reports, the global acute ischemic stroke treatment market was worth $9.21 billion in 2023. It is anticipated to reach $19.05 billion by the end of 2030 at a CAGR of 4%
The robust growth is due to the current trends in acute ischemic stroke treatment and diagnosis, highlighting a move toward advanced imaging technologies for timely and precise diagnosis. The increasing popularity of telemedicine and remote monitoring makes timely interventions more accessible. Furthermore, state-of-the-art methods for improving patient outcomes include customized treatment plans and novel therapeutic approaches.
Recent Developments
Last month,MicroVention announced the commercial availability of the LVIS EVO Intraluminal Support Device in the United States for treating wide neck intracranial aneurysms. Available in Europe since 2019, with over 12,000 units sold, the LVIS EVO is the first fully visible coil-assist intracranial stent in the U.S. market. The device features DFT wire construction and an advanced braid design for enhanced visualization, optimized opening and precise placement, ensuring wall apposition confirmation.
Price Performance
Shares of Terumo have risen 6.7% so far this year compared with the industry's 3.7% rise. The S&P 500 has witnessed an 18.2% rise in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Terumo carries a Zacks Rank #4 (Sell).
Some top-ranked stocks in the broader medical space are DaVita Inc. (DVA - Free Report) , Universal Health Services (UHS - Free Report) and Dexcom (DXCM - Free Report) .
DaVita, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 13.6%. DVA’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 29.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
DaVita’s shares have gained 34.2% compared with the industry’s 4.5% rise so far this year.
Universal Health Services, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 14.80%. UHS’ earnings surpassed estimates in each of the trailing four quarters, with the average being 8.12%.
Universal Health Services has gained 20.4% compared with the industry's 17.5% so far this year.
DexCom, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 22.9%. DXCM’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 34.10%.
DexCom’s shares have declined 9.4% against the industry's 3.5% increase so far this year.